OneSkin, founded by Brazilian PhD scientists in 2016, reports that it has now closed a Series A funding round led by Selva Ventures, together with contributions from PLUS Capital, Unilever Ventures, Able Partners, SOSV, and Meta Planet. This brings the accumulated capital of the firm to 20 million US dollars.
The goal of the OneSkin team is the research and development of topical treatments that promote skin longevity. The brand’s efforts have led to the development of the peptide OS-01, which is claimed to reverse the aging of the skin by preventing the accumulation of “old”, non-dividing senescent cells, as well as shield skin cells from DNA damage. OS-01 is already available on the market in several different products offered by the company.
Senescent cells have been the focus of a significant amount of biogerontological research in recent years. Scientists claim that every cell in the human body has a limited capacity for division, governed by genetic factors. When the cells reach the point in their lifecycle where their ability to divide is permanently halted, they remain in a minimally-functional state in the tissue types they inhabit.
Senescent cells are characterized by the release of cytokines and other molecules that produce inflammation, and some investigators even claim that they are the main cause of the high, chronic inflammation levels that are common among the elderly. They are also cited as a major contributing factor to the visible signs of aging in the skin and connective tissue. OneSkin’s approach is therefore to target the underlying causes of skin aging by preventing the accumulation of these senescent cells.
Source: OneSkin Closes Series A Investment Round, Fueling The Future of Skin Longevity With Advanced Research
https://www.prnewswire.com/news-releases/oneskin-closes-series-a-investment-round-fueling-the-future-of-skin-longevity-with-advanced-research-302303502.html